Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Drug interactions: regulatory aspects]

B Saint-Salvi1

  • 1Agence du Médicament, Direction de l'Evaluation, Saint-Denis, France.

Therapie
|May 1, 1995
PubMed
Summary
This summary is machine-generated.

The French Medicines Agency

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Clinical practice guideline: medical and nonmedical therapeutic strategies for smoking cessation. Bit of therapeutic practice: management and current practice in smoking cessation].

Revue des maladies respiratoires·2003
Same author

Hierarchization of animal teratology findings for improving the human risk evaluation of drugs.

Reproductive toxicology (Elmsford, N.Y.)·2000
Same author

No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin and its enantiomers.

Pharmacology & toxicology·1988
Same author

A study of the interaction of roxithromycin with theophylline and carbamazepine.

The Journal of antimicrobial chemotherapy·1987
Same author

Pharmacokinetics of ofloxacin and theophylline alone and in combination.

Infection·1986
Same journal

Pharmacology of pruritus (pathophysiology, therapeutic targets).

Therapie·2026
Same journal

Barriers to prescribing methylphenidate for adults with ADHD: A qualitative study.

Therapie·2026
Same journal

[Self-medication and its factors amongst Navymen aboard surface ships of the French Navy at sea: A descriptive study].

Therapie·2026
Same journal

Subacute cutaneous lupus erythematosus induced by ticagrelor: Recurrence after rechallenge.

Therapie·2026
Same journal

Multiple HIV virological failures related to bictegravir-valproic acid interaction evidenced by therapeutic drug monitoring: A retrospective study.

Therapie·2026
Same journal

Indication-related misuse of oral fluoroquinolones in adults by general practitioners in France.

Therapie·2026
See all related articles

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Clinical Pharmacology
  • Regulatory Science

Context:

  • The French Medicines Agency's Drug Interactions working party addresses the critical need for accurate drug interaction information.
  • Ensuring patient safety requires rigorous evaluation of potential adverse drug events.
  • Harmonizing drug interaction data across pharmacological classes is essential for healthcare professionals.

Purpose:

  • To establish a systematic process for selecting and updating clinically relevant drug interactions.
  • To ensure that drug interaction information is based on robust pharmacovigilance data and new scientific evidence.
  • To harmonize labeling and provide clear recommendations for co-prescription management.

Summary:

  • The Drug Interactions working party analyzes observed cases and new data to identify clinically significant drug interactions.

Related Experiment Videos

  • Conclusions are approved by the French Medicines Registration Committee, leading to harmonized labeling in drug summaries.
  • This process results in yearly updates to drug interaction information and community-level acknowledgment of labeling.

    • Impact:

    • Improved consistency in drug interaction information for similar pharmacological classes.
    • Enhanced accessibility of up-to-date drug interaction data through yearly publications.
    • Standardized labeling of drug interactions, including mechanisms, recommendations, and co-prescription guidance, at a community level.